As PhII data looms, Chugai inks a $205M stem cell deal with Athersys – FierceBiotech
CNNMoney |
As PhII data looms, Chugai inks a $205M stem cell deal with Athersys
FierceBiotech Cleveland-based Athersys is pocketing a $10 million upfront payment from Chugai in exchange for licensing rights to the biotech's stem cell treatment for repairing stroke damage. The Japanese pharma company, which has close relations with Roche, also … Athersys Lands Japan Partner for Stroke Therapy Ahead of Key Study Data Athersys and Chugai Enter License Agreement and Collaboration to Develop … Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M … |
